Silibinin improves cognitive impairment by reducing the expression of inflammatory factors such as interleukin 1 beta (IL-1β) and IL-6 and suppressing the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway (Jin et al., 2016 ▶; Song et al., 2017 ▶, 2018). Here, IL6 is linked to Cognitive impairment.